Neurocrine Biosciences Inc (NBIX) is a Healthcare · Drug Manufacturers - Specialty & Generic company listed on NASDAQ. Price $146.23 (-3.69%), Market cap $15.99B, P/E ratio 24.47, 52-week low–high $119.12 ~ $161.32.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for
Financial statements, price targets, institutional (13F) holdings and related news for Neurocrine Biosciences Inc are updated in real time on BlackAll Trade.
Neurocrine Biosciences Inc trades at $146.23 (-3.69%). Real-time quotes and charts are available on BlackAll Trade.
Neurocrine Biosciences Inc has a market cap of about $15.99B. Its P/E ratio is 24.47.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The